Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Oryzon Genomics S.A.
  6. Summary
    ORY   ES0167733015

ORYZON GENOMICS S.A.

(ORY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
3.4(c) 3.405(c) 3.4(c) 3.36(c) 3.38 Last
28 698 59 005 53 891 26 499 78 966 Volume
-1.16% +0.15% -0.15% -1.18% +0.60% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -4,33 M -5,10 M -5,10 M
Net cash position 2021 13,0 M 15,3 M 15,3 M
P/E ratio 2021 -36,5x
Yield 2021 -
Sales 2022 3,29 M 3,87 M 3,87 M
Net income 2022 -6,19 M -7,29 M -7,29 M
Net cash position 2022 0,23 M 0,27 M 0,27 M
P/E ratio 2022 -32,5x
Yield 2022 -
Capitalization 177 M 209 M 209 M
EV / Sales 2021 -
EV / Sales 2022 53,9x
Nbr of Employees 44
Free-Float 80,3%
More Financials
Company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1... 
More about the company
All news about ORYZON GENOMICS S.A.
07/29ORYZON GENOMICS S A : Reports Results and Corporate Update for First Half Ended ..
AQ
07/29Oryzon Genomics S.A. Announces Audited Earnings Results for the Second Quarte..
CI
07/13ORYZON GENOMICS S A : receives approval to start EVOLUTION Phase IIb trial with ..
AQ
07/13Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial wit..
CI
07/13ORYZON GENOMICS S A : Wins Regulatory Nod to Further Study Vafidemstat in Schizo..
MT
07/09Oryzon Genomics S.A. Presents Safety and Efficacy Data of Vafidemstat from th..
CI
07/09ORYZON GENOMICS S A : COVID-19 Drug Shown Safe, Anti-Inflammatory in Preliminary..
MT
07/09ORYZON GENOMICS S A : presents safety and efficacy data of vafidemstat from the ..
PU
06/21ORYZON GENOMICS S A : to present new clinical data and corporate updates at inte..
PU
06/15Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Tr..
CI
06/15ORYZON GENOMICS S A : announces FDA approval of IND for PORTICO, a Phase IIb tri..
PU
06/11ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Posit..
CI
06/11ORYZON GENOMICS S A : presents iadademstat ALICE 30-month data at EHA-2021, conf..
PU
05/13ORYZON to Present New Clinical Data
CI
05/13ORYZON GENOMICS S A : to present new clinical data and corporate updates at inte..
PU
More news
News in other languages on ORYZON GENOMICS S.A.
07/29ORYZON GENOMICS S A : Q2 2021 Financial Results CNMV format ( Spanish only)
07/29ORYZON GENOMICS S A : anuncia sus resultados y avances en el primer semestre de ..
07/12ORYZON GENOMICS : Invest Securities confirme son conseil
07/09ORYZON GENOMICS S A : presenta datos de seguridad y eficacia de vafidemstat del ..
06/21ORYZON GENOMICS S A : presentará nuevos datos clínicos y actualizaciones corpora..
More news
Chart ORYZON GENOMICS S.A.
Duration : Period :
Oryzon Genomics S.A. Technical Analysis Chart | ORY | ES0167733015 | MarketScreener
Technical analysis trends ORYZON GENOMICS S.A.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,36 €
Average target price 10,50 €
Spread / Average Target 213%
EPS Revisions
Managers and Directors
Carlos Manuel Buesa Arjol Chairman, President & Chief Executive Officer
Enric Rello Condomines Chief Operating & Financial Officer
Sonia Paloma Gutierrez Chief Clinical Operations
Jordi Xaus Chief Scientific Officer
Xavier Perpinya Ribera Head-Internal Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ORYZON GENOMICS S.A.-4.00%209
MODERNA, INC.321.80%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.91%49 407
CELLTRION, INC.-25.63%31 021
SEAGEN INC.-12.32%27 940